Charles Schwab
SCMP

Charles Schwab’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Charles Schwab’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-190,531
Closed -$3.42M – 3096
2017
Q4 		$3.42M Sell
190,531
-103,650
-35% -$1.28M ﹤0.01% 2107
2017
Q3 		$3.47M Buy
294,181
+47,385
+19% +$532K ﹤0.01% 2066
2017
Q2 		$2.59M Buy
246,796
+66,493
+37% +$678K ﹤0.01% 2134
2017
Q1 		$1.98M Buy
180,303
+4,104
+2% +$47.6K ﹤0.01% 2200
2016
Q4 		$2.39M Sell
176,199
-17,690
-9% -$247K ﹤0.01% 2101
2016
Q3 		$2.39M Buy
193,889
+3,138
+2% +$37K ﹤0.01% 2053
2016
Q2 		$2.09M Sell
190,751
-9,806
-5% -$110K ﹤0.01% 2049
2016
Q1 		$2.19M Sell
200,557
-28,759
-13% -$363K ﹤0.01% 2004
2015
Q4 		$3.96M Sell
229,316
-62,029
-21% -$1.11M 0.01% 1677
2015
Q3 		$5.79M Buy
291,345
+66,396
+30% +$1.52M 0.01% 1374
2015
Q2 		$3.7M Buy
224,949
+156,874
+230% +$2.72M 0.01% 1745
2015
Q1 		$1.06M Buy
68,075
+4,347
+7% +$67.4K ﹤0.01% 2349
2014
Q4 		$911K Buy
63,728
+20,228
+47% +$214K ﹤0.01% 2391
2014
Q3 		$283K Hold
43,500
– – ﹤0.01% 2830
2014
Q2 		$301K Buy
43,500
+14,100
+48% +$99.7K ﹤0.01% 2860
2014
Q1 		$211K Hold
29,400
– – ﹤0.01% 2933
2013
Q4 		$277K Hold
29,400
– – ﹤0.01% 2842
2013
Q3 		$184K Hold
29,400
– – ﹤0.01% 2947
2013
Q2 		$195K Buy
+29,400
New +$233K ﹤0.01% 2911

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Charles Schwab's SCMP Position: Q1 2018 in Review

Charles Schwab sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 190,531 shares — an estimated $3.42M sold.

Charles Schwab first reported a position in SCMP in Q2 2013 and held it in 19 quarters. The position peaked at $5.79M in Q3 2015. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Charles Schwab reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Charles Schwab sold 190,531 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $3.42M.
  • Charles Schwab first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 19 quarters.
  • Charles Schwab's Sucampo Pharmaceuticals, Inc. position peaked at $5.79M in Q3 2015.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Charles Schwab's 13F filing for Q1 2018, filed 7 May 2018.